Jinbo Biotechnology, known as the "first medical beauty concept stock" on the Beijing Stock Exchange (BSE), has made significant progress in its 2 billion yuan private placement and strategic investor introduction. The placement target is a company owned by Zhong Shanshan, founder of Nongfu Spring. Notably, another entity under Zhong Shanshan recently acquired a 5% stake in Jinbo Biotechnology, becoming the listed company's second-largest shareholder.

Jinbo Biotechnology announced on the evening of September 19 that the company received an "Acceptance Notice" issued by the BSE on September 18. After reviewing the company's application documents for issuing shares to specific targets, the BSE determined that they comply with the relevant requirements of the "Beijing Stock Exchange Listed Company Securities Issuance and Listing Review Rules" and accepted the application.

According to the announcement, this issuance is a targeted placement with a determined issuer, specifically Yangshengtang Co., Ltd. Zhong Shanshan holds a 98.38% stake in Yangshengtang and serves as its controlling shareholder and actual controller.

The announcement describes Yangshengtang as a modern high-tech enterprise specializing in the production and operation of health products. After more than two decades of development, the company's business spans multiple sectors including soft drinks, food, biopharmaceuticals, cosmetics, pharmaceutical health products, and scientific research.

Jinbo Biotechnology's share issuance price is set at 278.72 yuan per share, with plans to issue no more than 7,175,660 shares, expecting to raise a total of no more than 2 billion yuan. After deducting issuance expenses, the funds will be used for the Humanized Collagen Protein FAST Database and Product Development Platform project and supplementing working capital, focusing on the company's main business operations.

Notably, the share transfer between the company's controlling shareholder and actual controller Yang Xia and Jiushi Management Consulting (Hangzhou) Partnership (Limited Partnership) was completed recently. Yang Xia transferred 5,753,267 shares of Jinbo Biotechnology to Hangzhou Jiushi for 1.403 billion yuan, with Hangzhou Jiushi's shareholding ratio rising from 0 to 5%. According to reports, penetrating through Hangzhou Jiushi's equity structure reveals that Yangshengtang holds over 99% of the stake.

After completion of the private placement, Yang Xia will directly hold 62,013,705 company shares, representing 50.73% of the total share capital after issuance, with Yang Xia remaining as the company's controlling shareholder and actual controller.

Jinbo Biotechnology's core business focuses on the research, development, production, and sales of high-end implant-grade medical devices using Type A recombinant humanized collagen protein as the core raw material. The company's end products are primarily used in injectable medical anti-aging and medical beauty plastic surgery; secondarily in reproductive health, surgery, dermatology, ENT/oral, and colorectal departments for restorative treatments; and to a lesser extent in anti-aging repair skincare.

The company maintained growth momentum in the first half of this year. China Galaxy Securities research analysis indicates that the company possesses globally leading full industrial chain capabilities in Type A recombinant humanized collagen protein, with internationalization and capacity expansion expected to open up long-term growth space.

In the secondary market, Jinbo Biotechnology experienced a significant rally in the first half of this year, with share prices doubling and once becoming the "largest market cap stock" on the BSE. The stock has recently weakened, closing at 295.98 yuan per share on September 19, with a total market capitalization of 34.1 billion yuan, slightly below Betery.